2.5.21 | Policy
SWHR Urges Biden Administration to Extend Postpartum Medicaid Coverage
SWHR signed onto a letter urging swift action from the Centers for Medicare and Medicaid Services (CMS) to approve pending […]
12.8.20 | Policy
SWHR Urges Congress to Complete Work on FY21 Appropriations
SWHR signed onto a letter led by the American Society for Microbiology (ASM) and the American Association for the Advancement […]
12.8.20 | Policy
SWHR Urges President-Elect Biden to Prioritize NIH Funding
SWHR and nearly 350 other organizations signed onto a letter to President-Elect Biden discussing the importance of federal investment in […]
12.8.20 | Research and Clinical Trials
SWHR Comments on Sex & Gender Considerations in NIH-Wide COVID-19 Strategic Plan
The Society for Women’s Health Research (SWHR) submitted comments in response to the recently released NIH-Wide Strategic Plan for COVID-19 […]
12.8.20 | Research and Clinical Trials
SWHR Supports FDA Recommendations to Include Younger Women in Breast Cancer Research
The Society for Women’s Health Research (SWHR) submitted comments in response to a newly released U.S. Food and Drug Administration […]
12.8.20 | Maternal Health
SWHR Calls for Congressional Approval of Maternal Health Bills
In a push to see maternal health bills included in a year-end legislative package, the Society for Women’s Health Research […]
12.3.20 | Coronavirus
SWHR Calls on Congress to Strengthen Public Health Funding in FY21 Budget
SWHR joined more than 75 organizations in calling for strong funding for government public health and biomedical research agencies for […]
12.2.20 | Endometriosis
SWHR Urges Congressional Leadership to Prioritize Endometriosis Research Funding
SWHR sent a letter to House and Senate leadership this week in support of endometriosis’ inclusion as an eligible condition […]
11.23.20 | Research and Clinical Trials
SWHR Comments to FDA on MDUFA Reauthorization for Fiscal Years 2023-2027
The Society for Women’s Health Research (SWHR) submitted comments as a follow-up to the U.S. Food and Drug Administration (FDA) […]
10.16.20 | Alzheimer's Disease
SWHR Input to ICER on Assessment of New Alzheimer’s Disease Treatment
SWHR provided open input to the Institute for Clinical and Economic Review (ICER) on contextual considerations surrounding Alzheimer’s disease (AD) […]
